AU2023241819A1 - Notch1 and notch4 decoys and methods of use - Google Patents

Notch1 and notch4 decoys and methods of use Download PDF

Info

Publication number
AU2023241819A1
AU2023241819A1 AU2023241819A AU2023241819A AU2023241819A1 AU 2023241819 A1 AU2023241819 A1 AU 2023241819A1 AU 2023241819 A AU2023241819 A AU 2023241819A AU 2023241819 A AU2023241819 A AU 2023241819A AU 2023241819 A1 AU2023241819 A1 AU 2023241819A1
Authority
AU
Australia
Prior art keywords
fusion protein
notch
disorder
notchl
notch4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023241819A
Other languages
English (en)
Inventor
Jan Kitajewski
Timothy SARGIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois at Urbana Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois at Urbana Champaign, University of Illinois System filed Critical University of Illinois at Urbana Champaign
Publication of AU2023241819A1 publication Critical patent/AU2023241819A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2023241819A 2022-04-01 2023-03-24 Notch1 and notch4 decoys and methods of use Pending AU2023241819A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263326316P 2022-04-01 2022-04-01
US63/326,316 2022-04-01
PCT/US2023/064896 WO2023192802A1 (en) 2022-04-01 2023-03-24 Notch1 and notch4 decoys and methods of use

Publications (1)

Publication Number Publication Date
AU2023241819A1 true AU2023241819A1 (en) 2024-11-07

Family

ID=86054213

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023241819A Pending AU2023241819A1 (en) 2022-04-01 2023-03-24 Notch1 and notch4 decoys and methods of use

Country Status (6)

Country Link
US (1) US20250223332A1 (https=)
EP (1) EP4504766A1 (https=)
JP (1) JP2025511221A (https=)
AU (1) AU2023241819A1 (https=)
CA (1) CA3254329A1 (https=)
WO (1) WO2023192802A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
DE69332197T2 (de) 1992-03-13 2003-04-17 Organon Teknika B.V., Boxtel Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
TW201329105A (zh) * 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類ｎｏｔｃｈ１引誘物
WO2017205651A1 (en) * 2016-05-25 2017-11-30 The Trustees Of Columbia University In The City Of New York Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling

Also Published As

Publication number Publication date
JP2025511221A (ja) 2025-04-15
WO2023192802A1 (en) 2023-10-05
EP4504766A1 (en) 2025-02-12
CA3254329A1 (en) 2023-10-05
US20250223332A1 (en) 2025-07-10

Similar Documents

Publication Publication Date Title
JP6796184B2 (ja) 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
CN105518028B (zh) 与dll4和vegf特异性结合的新型双靶向蛋白及其用途
CN101802002B (zh) 结合人蛋白酪氨酸磷酸酶β（HPTPβ）的抗体及其用途
CN112566940B (zh) 多特异性wnt替代分子和其用途
CN107080843A (zh) 眼病的治疗
JP2002534359A (ja) 血管内皮細胞増殖因子アンタゴニストとその用途
TW201920242A (zh) Glp-2融合多肽及用於治療及預防胃腸病症之用途
TW201710296A (zh) ＲＧＭａ結合蛋白質及其使用
JP2021520195A (ja) Ｃ３結合薬及びその使用方法
US9878016B2 (en) IGFBP-3 derivatives and uses thereof
Nguyen et al. SZN-413, a FZD4 agonist, as a potential novel therapeutic for the treatment of diabetic retinopathy
CA2458565A1 (en) New angiogenesis inhibitors based on soluble cd44 receptor hyaluronic acid binding domain
AU2002326277A1 (en) New drug
US20250223332A1 (en) Notch1 and notch4 decoys and methods of use
CN121568704A (zh) 用于泪腺再生的wnt替代剂和方法
KR20240034671A (ko) 항-ptk7 항체 및 이의 용도
US11026996B2 (en) Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
JP2023533038A (ja) 補体経路阻害剤及び血管新生阻害剤を含む融合タンパク質並びにその使用
KR20250128899A (ko) Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도
CN118922443A (zh) 结合VEGF和Tie2的融合蛋白及其用途
WO2023083243A1 (zh) 一种抗il-17/vegf双功能融合蛋白及其用途
BR122024027449A2 (pt) Anticorpo anti-rgma isolado e composição farmacêutica compreendendo o mesmo
BR112015000800B1 (pt) Método para a redução da viscosidade de um anticorpo, anticorpos biespecíficos, composição farmacêutica compreendendo um anticorpo, método para preparação de um anticorpo biespecífico e anticorpos biespecíficos bivalentes